Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 144

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 144
---
 Business Combination and related transactions as if they
had been completed on December 31, 2023. The unaudited pro forma condensed combined statement of operations for the year ended December
31, 2023, gives effect to the Business Combination and related transactions as if they had been completed on January 1, 2023. These periods
are presented on the basis that PBAX is the acquirer for accounting purposes.

The pro forma adjustments
reflecting the consummation of the Business Combination and the related transaction are based on certain currently available information
and certain assumptions and methodologies that PBAX management believes are reasonable under the circumstances. The unaudited condensed
combined pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available
and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible
that the differences may be material. PBAX management believes that its assumptions and methodologies provide a reasonable basis for
presenting all of the significant effects of the Business Combination and the related transactions based on information available to
management at this time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the
unaudited pro forma condensed combined financial information.

The unaudited pro forma
condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost
savings that may be associated with the Business Combination. The unaudited pro forma condensed combined financial information is not
necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination and
related transactions taken place on the dates indicated, nor are they indicative of the future results of operations or financial position
of the post-combination company. They should be read in conjunction with the historical financial statements and notes thereto of PBAX
and Legacy CERo.

Note 2. Accounting Policies and Reclassifications

After consummation of the
Business Combination, management will perform a comprehensive review of the two entities’ accounting policies. As a result of the
review, management may identify differences between the accounting policies of the two entities which, when conformed, could have a material
impact on the financial statements of the post-combination company. Based on its initial analysis, management did not identify any differences
that would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited pro